12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Sildenafil induces hyperalgesia via activation of the NO-cGMP pathway in the rat neuropathic pain model.

      1 , , ,
      Inflammopharmacology
      Springer Nature

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Persistent stimulation of nociceptors and C-fibers by tissue injury causes hyperalgesia and allodynia by sensitization of nociceptors and facilitation of synaptic transmission in the spinal cord. The important participant in the inflammatory response of injured peripheral nerve may be nitric oxide (NO). The aim of the present study was to test the sensitivity of PDE5 inhibitor sildenafil in chronic constriction injury (CCI) model a rat model of neuropathic pain. Sciatic nerve injury is associated with development of hyperalgesia 14 days after the nerve ligation. Sildenafil (100 and 200 microg/rat, i.t.) produced a significant decrease in pain threshold, which in lower dose did not alter the nociceptive threshold. The hyperalgesic effect of sildenafil was blocked by L-NAME and methylene blue (MB), which on per se treatment showed antinociceptive effect in nerve ligated rats. The results from the present study indicated that the major activation of NO-cGMP pathway in the chronic constriction injury model of neuropathic pain. The aggravation of hyperalgesic response might be due to the increased cGMP levels resulting in PKG-I activation and its upregulation.

          Related collections

          Author and article information

          Journal
          Inflammopharmacology
          Inflammopharmacology
          Springer Nature
          0925-4692
          0925-4692
          Mar 2006
          : 14
          : 1-2
          Affiliations
          [1 ] Pharmacology R and D, Panacea Biotec Ltd, Lalru, 140501 Punjab, India.
          Article
          10.1007/s10787-006-1511-y
          16835709
          3610bf0d-b049-4c5a-bcca-efe80e2e930a
          History

          Comments

          Comment on this article